321例耐多药结核病耐药情况分析

摘要/Abstract

摘要： 目的了解原发性与获得性MDR-TB患者年龄分布特征及临床耐药情况，为MDR-TB的防治提供科学依据。方法收集广州市胸科医院2005年1月至2010年12月期间收治的321例MDR-TB患者（原发性耐多药47例、获得性耐多药274例）耐药情况等资料，将患者年龄分为4组，其中＜20岁组5例，20～岁组183例，40～岁组105例，60～岁组28例，分别分析其耐药情况。结果原发性耐多药和获得性耐多药患者中，均以20～岁组的比例最高，分别有30例（63.8%，30/47）和153例(55.8%，153/274)，但两者与不同年龄组患者［原发性耐多药＜20岁组1例（2.1%），40～岁组14例（29.8%），60～岁组2例（4.3%）；获得性耐多药＜20岁组4例（1.5%），40～岁组91例（33.2%），60～岁组26例（9.5%）］的比较，差异无统计学意义（Fisher确切概率法, P=0.515）。不同年龄组耐一线药分布（分别耐HR、HRE、HRS、HRSE），在原发性耐多药患者中，＜20岁组1例（耐HRS 1例，其余0例）；20～岁组30例（耐HR 10例，耐HRE 13例，耐HRS 5例，耐HRSE 2例）；40～岁组14例（耐HR 4例，耐HRE 7例，耐HRS 3例，耐HRSE 0例）；60～岁组2例（耐HRE和HRS各1例，耐HR和HRSE均0例）］。而获得性耐多药中，＜20岁组4例(耐HR、HRE、HRS、HRSE各1例，均占25.0%）；20～岁组153例（耐HR 56例，占36.6%；耐HRE 26例，占17.0%；耐HRS 46例，占30.1%；耐HRSE 25例，占16.3%）；40～岁组91例（耐HR 34例，占37.4%；耐HRE 26例，占28.6%；耐HRS 17例，占18.7%；耐HRSE 14例，占15.4%）；60～岁组26例（耐HR和HRS各5例，均占19.2%；耐HRE 13例，占50.0%；耐HRSE 3例，占11.5%），差异有统计学意义（Fisher确切概率法, P=0.030）；进一步两两比较，20～岁组和60～岁组间的分布差异有统计学意义（χ²=14.32，P=0.002）。原发和获得性耐多药患者耐二线药物［阿米卡星（Am）、克拉霉素（Clr）、左氧氟沙星（Lfx）、莫西沙星（Mfx）、对氨基水杨酸钠（PAS）、利福布丁（Rfb）、丙硫异烟胺（Pto）共7种］都以耐1～2种为最多，分别为25例（53.2%）、115例（42.0%），但两组分布差异无统计学意义（χ²=3.123，P=0.210）。结论原发性和获得性MDR-TB以年轻患者为主，耐多药情况较为严重，应加强结核病患者的诊治，减少耐多药现象。

关键词: 结核, 抗多种药物性, 抗药性, 多种, 细菌

Abstract: Objective To understand the age distribution of primary and acquired MDR-TB patients and the status of their drug resistance, and provide a scientific basis for prevention and treatment of MDR-TB. Methods We made a retrospective analysis of MDR-TB cases admitted in our hospital between January 2005 and December 2010 (47 cases of primary and 274 cases of acquired multidrug-resistant cases respectively). Patients were divided into 4 groups by age, 5 cases in ＜20 age group, 183 cases in 20- age group, 105 cases of 40- age group, and 28 cases of 60- age group, respectively, to analyze the status of TB drug resistance. Results In 47 primary and 274 acquired MDR cases,age between 20 to 30 had the highest number of cases, which were 30(63.8%)and 153 (55.8%) respectively. However the difference of primary and acquire MDR-TB distribution in different age group is not statistically significant(primary MDR-TB: 1 case of ＜20 age group (2.1%), 14 cases of age over 40 (29.8%), 2 cases of age over 60(4.3%), acquired MDR-TB: 4 cases of ＜20 age group(1.5%), 91 cases of age over 40 (33.2%), 26 cases of age over 60 (9.5%). (Fisher’s exact test, P=0.515). As for the distribution of the first-line drug resistance (respectively, resistance to the HR, HRE, HRS and HRSE), in primary MDR cases, 1 cases in ＜20 age group (resistant to HRS), 30 cases of age over 20 (10 resistant to HR, 13 to HRE，5 to HRS, and 2 to HRSE), 14 cases of age over 40 (4 resistant to HR, 7 to HRE, 3 to HRS), 2 cases of age over 60 (1 resistant to HRE and 1 to HRS). In acquired MDR-TB cases, 4 cases in ＜20 age group (resistant to HR, HRE, HRS and HRSE respectively), 153 cases of age over 20 (56 (36.6%) resistant to HR, 26(17.0%) to HRE，46(30.1%) to HRS, and 25(16.3%) to HRSE), 91 cases of age over 40 (34(37.4%) resistant to HR, 26(28.6%) to HRE, 17(18.7%) to HRS, 14(15.4%)to HRSE), 26 cases of age over 60 (5(19.2%) resistant to HR and 5(19.2%) to HRS, 13(50.0%)to HRE, 3(11.5%) to HRSE). The distribution is statistically significant different between different age group (Fisher’s exact test, P=0.030).Further multiple comparison found that the difference is statistically significant between 20- age group and 60- age group. In primary MDR and acquired MDR cases, they were mainly resisted to one or two second-line drugs(seven drugs in total: amikacin (Am), clarithromycin (Clr), levofloxacin (Lfx), moxifloxacin (Mfx), sodium aminosalicylate (PAS), rifabutin (Rfb), propylthiouracil isonicotinoyl amine (Pto)］, the resistant rate were 25(53.2%) and 115(42.0%) respectively, however the difference is not statistically significant (χ²=3.123, P=0.211). Conclusion The primary and acquired MDR-TB predominantly affects young people, and the situation of MDR-TB is serious. We should strengthen the diagnosis and treatment of TB patients, and reduce the incidence of multi-drug-resistant.

Key words: Tuberculosis,multidrug-resistant, Drug resistance,multiple,bacterial

何佩贤黎婉媚康莉娟. 321例耐多药结核病耐药情况分析[J]. 中国防痨杂志, 2012, 34(8): 514-518.

HE Pei-xian, LI Wan-mei, KANG Li-juan. An analysis of 321 cases of multidrug-resistance tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2012, 34(8): 514-518.

[1]	刘晓莉, 雷丽梅, 郭周莉, 黄殷, 徐静, 赵霞, 王燕, 付莉. 结核病患者产生病耻感与领悟社会支持的相关性研究[J]. 中国防痨杂志, 2020, 42(9): 1002-1008.
[2]	中国防痨协会学术工作委员会《中国防痨杂志》编辑委员会. 抗结核药品固定剂量复合制剂的临床使用专家共识[J]. 中国防痨杂志, 2020, 42(9): 885-893.
[3]	靳鸿建. 我国县级结核病防治服务体系建设及防治工作亟需加强——一位老防痨工作者的意见和建议[J]. 中国防痨杂志, 2020, 42(9): 896-902.
[4]	张灿有, 夏辉, 成君. Ⅱ级生物安全柜在结核病实验室中的检测及报告要求[J]. 中国防痨杂志, 2020, 42(9): 903-909.
[5]	周林, 刘二勇, 孟庆琳, 陈明亭, 周新华, 高微微, 林明贵, 谢汝明. 《WS 288—2017 肺结核诊断》标准实施后肺结核诊断质量评估分析[J]. 中国防痨杂志, 2020, 42(9): 910-915.
[6]	刘二勇, 王前, 周林, 张国钦, 张修磊, 马永成, 杨枢敏, 王毳, 孟庆琳, 陈明亭, 林明贵, 屠德华. 我国部分地区病原学检测阴性肺结核诊断质量现状分析[J]. 中国防痨杂志, 2020, 42(9): 916-920.
[7]	孟庆琳, 李进岚, 林定文, 马永成, 侯双翼, 刘年强, 周林. 结核病防治从业人员对新的结核病标准相关知识知晓情况调查分析[J]. 中国防痨杂志, 2020, 42(9): 921-925.
[8]	王前, 周林, 刘二勇, 赵雁林, 李涛, 陈明亭, 杨丽佳, 王嘉. 我国县级结核病定点医疗机构结核病诊断能力现况调查研究[J]. 中国防痨杂志, 2020, 42(9): 926-930.
[9]	李婷, 何金戈, 苏茜, 李京, 李运葵, 高文凤, 高媛, 杨文. 结核菌素试验在四川省布拖县HIV感染/AIDS患者中筛查结核感染的价值[J]. 中国防痨杂志, 2020, 42(9): 931-936.
[10]	李运葵, 何金戈, 苏茜, 李婷, 李京, 高文凤, 杨文, 毛光玉. 结核病症状筛查在四川省布拖县HIV感染/AIDS患者中发现结核病患者的价值[J]. 中国防痨杂志, 2020, 42(9): 937-941.
[11]	苏茜, 夏勇, 逯嘉, 王丹霞, 何金戈. 2009—2018年四川省0~14 岁儿童肺结核流行特征分析[J]. 中国防痨杂志, 2020, 42(9): 942-947.
[12]	邓亚丽, 张天华, 刘卫平, 张宏伟, 马煜, 李鹏. 2014—2018年陕西省肺结核发病的时空聚集性分析[J]. 中国防痨杂志, 2020, 42(9): 948-955.
[13]	董晓, 赵珍, 刘年强, 王森路, 崔燕. 2009—2017年新疆维吾尔自治区老年肺结核发现特征分析[J]. 中国防痨杂志, 2020, 42(9): 956-961.
[14]	马廷龙, 韩毅, 程序, 刘志东. 超声抗结核药品电导入联合化疗对胸壁结核的疗效观察[J]. 中国防痨杂志, 2020, 42(9): 968-972.
[15]	南海, 张芸, 杨新婷, 段鸿飞. GeneXpert MTB/RIF对骨关节结核诊断价值的Meta分析[J]. 中国防痨杂志, 2020, 42(9): 973-980.

321例耐多药结核病耐药情况分析

An analysis of 321 cases of multidrug-resistance tuberculosis patients

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

友情链接